Open AccessTrial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
Author(s) -
Sonja Ständer,
Gil Yosipovitch,
Franz J. Legat,
J.P. Lacour,
C. Paul,
Joanrbutt,
Thomas Bieber,
L. Misery,
Andreas Wollenberg,
Adam Reich,
Faiz Ahmad,
Christophe Piketty
Publication year - 2020
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1908316
Subject(s) - prurigo nodularis , dermatology , medicine , prurigo
Prurigo nodularis is a chronic pruritic skin disease with multiple nodular skin lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the pathogenesis of prurigo nodularis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom